DC The wolf can answer these not so difficult questions you understand......
Gold Seeker Thursday, 03/26/15 02:41:25 PM
Re: None
Post # of 28529
DC, Your claim that AMDL Diagnostics is receiving royalties is totally bogus.
Answer: On June 6th 2013, we entered into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property. Pursuant to the terms of the Agreement, the total license fee shall be US$500,000, $100,000 of which UNI shall pay as an up-front license fee ($20,000 upon signing the agreement and $80,000 upon commencement of training UNI personnel at ADI facilities) and the remaining of which, UNI shall pay in 4 equal annual installments over the next 4 years. The License Agreement will become effective upon our receipt of the up-front license fee.
How are royalties being "funneled" to AMDL Diagnostics? They have no address, no email, no phone.
Answer: AMDL Diagnostics Inc. Bank Account with payments of "Direct Deposit"...
Also, the owner of the Onko Sure trademark is Radient, not AMDL Diagnostics.
Answer: Great analysis you understand...Trademarks owned by Radient...Which means Radient will file their past due annual filings prior to the takeover/stock exchange with Provista Diagnostics to the proposed 2010 LOI Reverse Merger..
The owner of DR-70 is AMDL Inc., whose name was changed to Radient Pharmaceuticals Inc,. AMDL Diagnostics has no ownership of any trademarks.
Answer: Good point Goldie...That is a clear sign that Radient will be reinstated...The trademarks used by SRL Limited India, Metropolis India, Uni-Pharma Taiwan, GCDX Scottsdale, and Provista Diagnostics Scottsdale, and Bertech Canada...And many unknowns....
5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”),
Answer: The agreement was between Uni-Pharma and AMDL Diagnostics Inc. an ongoing entity in Delaware and a wholly owned subsidiary of Radient Pharmaceuticals Corporation...
If we become the party to any type of bankruptcy action or proceeding that disrupts our business and ability to deliver the Tests, UNI has the right to use, market and sell the Tests and carry out any tasks to do same; provided however, sales made by UNI pursuant thereto, remain subject to the payment of royalty fees.
Answer: AMDL Diagnostics Inc. is an ongoing entity in Good Standing in Delaware. President Mac and Secretary Akio...
The Agreement shall continue until the earlier of expiration of the last patent issued to us for the Tests, when UNI terminates the agreement by discontinuing the offering of the Tests, or if UNI does not achieve sales necessary to meet the contractual minimum royalty payments for two consecutive fiscal quarters. Each party has the right to terminate the Agreement in certain circumstances, including a material breach under the Agreement or following a cure period associated with a government imposed prohibition against the sale of the licensed products.
The meaning of this statement..
The Agreement shall continue until the earlier of expiration of the last patent issued to us for the Tests, when UNI terminates the agreement by discontinuing the offering of the Tests, or if UNI does not achieve sales necessary to meet the contractual minimum royalty payments for two consecutive fiscal quarters. Each party has the right to terminate the Agreement in certain circumstances, including a material breach under the Agreement or following a cure period associated with a government imposed prohibition against the sale of the licensed products.
The commas mean "AND"
The agreement shall continue until the earlier of expiration of the last patent issued to us for the Tests and when UNI terminates the agreement by discontinuing the offering of the tests and or if UNI does not achieve sales necessary to meet the contractual minimum royalty payments for two consecutive fiscal quarters. Each party has the right to terminate the Agreement in certain circumstances, including a material breach under the Agreement or following a cure period associated with a government imposed prohibition against the sale of the licensed products.
The clause above has nothing to do with the agreement being terminated because the last patents expired. Uni-Pharma has not terminated the agreement as we know of..It is possible Uni-Pharma did not achieve sales necessary to meet the contractual minimum royalty payments for two consecutive fiscal quarters...It could be possible that AMDL Diagnostics Inc.terminated Uni-Pharma...Could that be why Metropolis Cancer8 a/k/a Onko-Sure is selling our Cancer tests..The trademarks Onko-Sure and Dr-70 can be used by AMDL Diagnostics Inc. anytime they wish..AMDL Diagnostics Inc. has been using the two Trademarks since it was incorporated in 2010..
AI
